Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chitosan + calcium carbonate is a composite biomaterial that combines chitosan, a natural polysaccharide derived from crustacean shells, with calcium carbonate (CaCO3). This composite material is primarily developed for hemostatic (blood clotting) and wound healing applications. The combination leverages chitosan's positive charge from protonated amine groups, which interact electrostatically with negatively charged red blood cells and platelets to induce thrombus formation and activate the coagulation cascade. The material demonstrates enhanced water absorption ability (up to 460%) compared to single components alone, which helps concentrate blood coagulation factors and platelets. In preclinical studies, the composite significantly reduced blood clotting time from 31 seconds for CaCO3 alone to 16 seconds, and accelerated wound healing from 12 days to 9 days in rat models. The material is typically prepared via wet-granulation methods and exhibits biocompatibility, biodegradability, and antimicrobial properties. The calcium carbonate component provides structural support and may contribute to the hemostatic properties by participating in the coagulation cascade.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chitosan + calcium carbonate.